Learning Objectives:

1. Review recent studies that have changed standard therapy for locally advanced gastroesophageal cancer including chemotherapy and immunotherapy

2. Review ongoing clinical trials and their rationale attempting to improve clinical outcomes and/or treatment tolerability, including pharmacogenomically directed therapy

3. Review understanding of ctDNA minimal residual disease as a prognostic biomarker, and current limitations as a predictive biomarker of therapeutic benefit.

Session date: 
Monday, August 9, 2021 - 12:00pm to 1:00pm
Location: 
Virtually
United States
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
Daniel Catenacci, MD